Calendar
event
Ex dividend date
09 Jun 2025
event_available
Last Dividend Payment
01 Jan 1970
About Biomerieux SA
Ticker
info
BIM
Trading on
info
PA
ISIN
info
FR0013280286
Industry
info
Diagnostics & Research
Sector
info
Healthcare
CEO
info
-
Headquarters
info
376 Chemin De l’Orme, Marcy-l'Étoile, undefined, France, 69280
Employees
info
14,147
Website
info
biomerieux.com
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Metrics
BasicAdvanced
Market cap
info
€12.9B
P/E ratio
info
34.35
EPS
info
€3.17
Dividend Yield
info
0.83%
Beta
info
0.65
Forward P/E ratio
info
22.73
EBIDTA
info
€1,000M
Ex dividend date
info
2025-06-09
Price & volume
Market cap
info
€12.9B
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
€0.90
Dividend yield
info
0.83%
Forward dividend per share
info
€0.90
Forward dividend yield
info
0.83%
Payout ratio
info
28.39%
Valuation
P/E ratio
info
34.35
Forward P/E
info
22.73
PEG ratio
info
1.82
Trailing P/E
info
34.35
Price to sales
info
3.12
Price to book
info
3.27
Earnings
EPS
info
€3.17
EPS estimate (current quarter)
info
€0.00
EPS estimate (next quarter)
info
€0.00
EBITDA
info
€1,000M
Revenues (TTM)
info
€4.12B
Revenues per share (TTM)
info
€34.89
Technicals
Beta
info
0.65
52-week High
info
€128.30
52-week Low
info
€100.95
50-day moving average
info
€108.51
200-day moving average
info
€115.85
Short ratio
info
0
Short %
info
0.00%
Management effectiveness
ROE (TTM)
info
9.49%
ROA (TTM)
info
8.23%
Profit margin
info
9.17%
Gross profit margin
info
€2.32B
Operating margin
info
17.33%
Growth
Quarterly earnings growth (YoY)
info
-25.80%
Quarterly revenue growth (YoY)
info
7.50%
Share stats
Outstanding Shares
info
118M
Float
info
44.7M
Insiders %
info
62.75%
Institutions %
info
21.54%
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-
-
-
Q3 • 24Beat
€1.82
€2.15
-15.35%
Q4 • 24Missed
€1.82
-
-
Q1 • 25Beat
€1.35
€2.19
-38.36%
Q2 • 25Missed
-
-
-
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
€785M
€67.2M
8.56%
Q1 • 25
€2.04B
€161M
7.88%
Q2 • 25
160.39%
139.58%
-7.99%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
0.00%
Q1 • 25
€5.37B
€1.43B
26.62%
Q2 • 25
NaN%
NaN%
0.00%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
€470M
-
€-97.3M
€275M
Q4 • 24
€318M
-
€-76.5M
€165M
Q2 • 25
-32.48%
-
-21.38%
-39.99%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Biomerieux SA share?
Collapse

Biomerieux SA shares are currently traded for undefined per share.

How many shares does Biomerieux SA have?
Collapse

Biomerieux SA currently has 118M shares.

Does Biomerieux SA pay dividends?
Collapse

Yes, Biomerieux SA does pay dividends.

What is Biomerieux SA 52 week high?
Collapse

Biomerieux SA 52 week high is €128.30.

What is Biomerieux SA 52 week low?
Collapse

Biomerieux SA 52 week low is €100.95.

What is the 200-day moving average of Biomerieux SA?
Collapse

Biomerieux SA 200-day moving average is €115.85.

Who is Biomerieux SA CEO?
Collapse

The CEO of Biomerieux SA is -.

How many employees Biomerieux SA has?
Collapse

Biomerieux SA has 14,147 employees.

What is the market cap of Biomerieux SA?
Collapse

The market cap of Biomerieux SA is €12.9B.

What is the P/E of Biomerieux SA?
Collapse

The current P/E of Biomerieux SA is 34.35.

What is the EPS of Biomerieux SA?
Collapse

The EPS of Biomerieux SA is €3.17.

What is the PEG Ratio of Biomerieux SA?
Collapse

The PEG Ratio of Biomerieux SA is 1.82.